###### Strengths and limitations of this study

-   This meta-analysis summarised the late outcomes of haematological changes and relevant nutritional deficiencies after Roux-en-Y gastric bypass (RYGB) by including a large sample and exclusion of small trials.

-   In our meta-analysis, there is not much uncertainty as to the effect of RYGB on development of anaemia, low ferritin and vitamin B~12~ deficiencies.

-   Our findings can be translated into clinical practice by implementing preoperation and postoperation surveillance of ferritin and vitamin B~12~ levels, and nutrient supplementation.

-   This study is limited by heterogeneity across studies without formal quality assessment.

Introduction {#s1}
============

Obesity is a complex metabolic disorder that is often associated with related comorbid conditions that require medical intervention, including cardiovascular disease, type 2 diabetes mellitus, dyslipidaemia, degenerative osteoarthritis and psychological disabilities, and pose a huge social burden.[@R1] The increasing prevalence and severity of obesity likely results from complex interactions of dietary intake, physical activity, genes and the environment.[@R2] [@R3] However, conventional medical treatment and lifestyle modification seldom yield satisfactory long-term results in obese people.[@R4] After more than 50 years' experience performing bariatric surgery, the procedure is now recommended for morbidly obese individuals, with proven long-lasting effects on weight reduction, remission of diabetes and cardiovascular complications and mortality.[@R7]

Over the past decades, Roux-en-Y gastric bypass (RYGB) has been a classical bariatric surgery with 85% of patients receiving this restrictive/malabsorptive procedure.[@R12] [@R13] In this procedure, gastric capacity is reduced by 90--95%. However, adverse effects such as nutritional deficiencies and gastrointestinal symptoms have been observed following RYGB, including disturbances of anatomical and physiological functions.[@R14] A wide range of prevalence and severity of anaemia after RYGB surgery has been reported and the related causes are not yet fully understood.[@R15] Therefore, we conducted a systematic review and meta-analysis of all published studies to obtain a pooled risk estimate of anaemia and to summarise the reported nutritional deficiencies relevant to anaemia during long-term follow-up of patients receiving RYGB surgery.

Methods {#s2}
=======

The methods for this systematic review and meta-analysis were developed according to recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA),[@R19] and the Meta-Analysis of Observational Studies in Epidemiology statements.[@R20]

Identification of trials {#s2a}
------------------------

We applied Medical Subjects Heading (MeSH) terms for keyword and text word searching with 'gastric bypass' as intervention term, and subject terms including 'anemia', 'hemoglobins', 'hematocrit', 'anemia, iron-deficiency', 'iron', 'ferritins', 'vitamin B~12~', 'vitamin B~12~ deficiency', 'folic acid', 'folic acid deficiency' and 'folate'. We searched all fields in MEDLINE (via PubMed), all text in Cochrane Library (including the Cochrane Database of Systematic Reviews; the Database of Abstracts of Reviews of Effects; and the Cochrane Register of Controlled Trials) and searched 'Roux-en-Y gastric bypass' in ClinicalTrials.gov website (<https://register.clinicaltrials.gov/>). The search was last updated on 16 May 2014 (see search query in online [supplementary appendix](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2014-006964/-/DC1) 1). The references of review articles on surgical treatment of obesity were examined manually to identify additional articles that were not found in the computerised databases.[@R17] [@R18] [@R21]

Eligibility criteria {#s2b}
--------------------

This meta-analysis targeted studies on treatment of morbid obesity patients (class III with body mass index (BMI) ≥40; or \>35 with comorbidities) using standard RYGB procedure. We included both laparoscopy and traditional open procedure. We included randomised controlled trials, case series, as well as observational studies that enrolled diabetic and non-diabetic patients. Studies were required to provide any outcome of (1) anaemia and anaemia-related parameters (haemoglobin, haematocrit) and/or (2) the relevant nutrient profiles including serum iron, ferritin, vitamin B~12~ or folate. Information of therapeutic and/or prophylactic nutrient supplementations was allowed to be included.

We excluded non-English articles and studies with gastric bypass surgeries carried out by procedures other than RYGB, patients aged \<18 years and studies with fewer than 100 participants. The threshold number of 100 was selected for practicality and to avoid the small study effects potentially distorting results of meta-analyses. Reports that did not present preoperation baseline data, or follow-up duration less than 12 months, were also excluded. [Figure 1](#BMJOPEN2014006964F1){ref-type="fig"} illustrates the literature search and study selection.

![Literature search and study selection.](bmjopen2014006964f01){#BMJOPEN2014006964F1}

Outcomes of interest {#s2c}
--------------------

The primary outcomes of interest in this meta-analysis were the proportions of patients who had anaemia, and iron, ferritin, folate and vitamin B~12~ deficiencies, after the surgery and the changes in percentage of the above outcomes from the baseline after more than 12 months follow-up. The secondary outcomes of interest included the mean haematocrit, haemoglobin, serum iron, ferritin, folate and vitamin B~12~ levels, and the changes in the above measurements from baseline. We did not define specific cut-off values for related nutrient deficiencies because different criteria were used in different studies.

Data extraction {#s2d}
---------------

Two physician reviewers (C-H C, T-C W) independently evaluated each identified study and extracted relevant characteristics, including quality of the studies. Disagreement on specific studies between the two reviewers was resolved through discussion. Extracted information included study characteristics (author, published year, study design and intended follow-up duration); patient characteristics (country, mean or median age, percentage of males and mean BMI); and number of study participants and outcomes. The quality of each study was assessed based on the proportion of participants missing during follow-up. The means of outcome measurements and proportions of deficiencies at baseline, and 6, 12, 24 and 36 months after surgery, were extracted. Outcomes reported at different time points other than the stated time frame were combined with the nearest time point. The changes in these measurements from the baseline (ΔCt) were also calculated as (Ct-Cb), with Ct and Cb being the outcome measurements at specific time points, and at baseline if data were available.

Statistical analysis {#s2e}
--------------------

For bariatric surgeries, there are substantial differences in preoperative treatment, RYGB procedures, and postoperative nutritional management and outcome monitoring. Accordingly, we applied the random effects model with an inverse variance weighting method to capture variations across studies, and calculated the pooled estimates for the outcomes of interest. For each outcome at specific time points, we calculated the summary estimates and their 95% CIs based on data from the total number of available participants at that time point. A continuity correction factor of 0.01 was used for studies that reported zero incidence for the outcomes. Lower bounds of the CIs smaller than zero were reframed at zero. For changes in outcome measurements at each time point from the baseline, the summary estimates with 95% CIs were computed according to the absolute difference (ΔCt) and corresponding variance \[Var(ΔCt)\] in each study, where \[Var(ΔCt)\] was indirectly estimated as \[Var(Ct)+Var(Cb)\], given that none of the studies provided the original data on SD. Statistical heterogeneity was evaluated by the I^2^ statistic, with a value of 50% or more illustrating a substantial level of heterogeneity. Publication bias was assessed by the funnel plot, Begg\'s test and Egger\'s test. STATA V.9.0 (StataCorp, College Station, Texas, USA) was used for the analyses. A two-sided p value of 0.05 was defined as statistical significance.

Results {#s3}
=======

We identified 468 English studies on RYGB surgeries for patients with obesity from computerised literature databases and reference lists of systematic reviews ([figure 1](#BMJOPEN2014006964F1){ref-type="fig"}). A total of 453 studies were excluded because they were review articles, research without nutrition profiles or relevant outcomes, procedures other than RYGB, or the number of subjects was less than 100. A total of 15 observational studies enrolling morbidly patients with obesity were included in this meta-analysis.[@R27] The number of study subjects ranged from 100 to 1125, totalling 5909 patients ([table 1](#BMJOPEN2014006964TB1){ref-type="table"}). Most of the studies were conducted in the USA; six were prospective.[@R27] [@R28] [@R32] [@R36] [@R37] [@R41] Four studies had an intended follow-up duration of 12 months, and 11 studies had more than 24 months follow-up. Four studies[@R27] [@R31] [@R32] [@R37] followed the postoperation patient profiles but with some reported at different time points. We included those data into the nearest stated time frame. Participants' mean age ranged from 36.1 to 48 years, and their mean BMI ranged from 41.8 to 50.1 kg/m^2^. The missing rates varied substantially between studies during the entire follow-up, ranging from 0 to 67.0%.

###### 

Study characteristics

  Year   Author            Country           Study type      Procedure     Case number   Intended follow-up (months)   Mean age (years)   Male (%)   Mean BMI   Nutrition management   12 months missing rate (%)
  ------ ----------------- ----------------- --------------- ------------- ------------- ----------------------------- ------------------ ---------- ---------- ---------------------- ----------------------------
  1992   Avinoah E         Israel            Prospective     NR            200           96                            36.1               29.0       NR         NR                     0
  1998   Brolin RE         USA               Prospective     NR            348           36                            --                 --         --         Oral MVI               12.6
  2006   Madan AK          USA               Retrospective   Laparoscopy   100           12                            --                 --         --         NR                     64.0
  2009   Toh SY            Australia         Retrospective   Laparoscopy   121           12                            48                 36.4       43.1       Oral MVI, B~12~\#      52.1
  2010   Avgerinos DV      USA               Retrospective   NR            206           20                            40.8               19.9       --         Oral MVI               0
  2011   von Drygalski A   USA               Prospective     Both          1125          48                            42                 11.2       50.1       Oral MVI               67.0
  2011   Cable CT          USA               Retrospective   Both          1009          36                            43.7               15.9       --         Oral MVI               28.6
  2012   Blume CA          Brazil            Retrospective   NR            170           36                            39.5               20.0       48.8       NR                     0
  2012   Dallal RM         USA               Retrospective   NR            590           12                            43.2               17.2       47.7       Fe\*                   0
  2012   Aarts EO          The Netherlands   Prospective     Laparoscopy   377           12                            43.4               27.1       46.8       Oral MVI               0
  2013   Moizé V           Spain             Prospective     Laparoscopy   294           60                            45.2               23         47.4       Oral MVI, B~12~\#      0
  2014   Gesquiere I       Belgium           Retrospective   Laparoscopy   164           60                            43                 25         41.8       Fe\*                   45.1
  2014   Obinwanne KM      USA               Retrospective   Laparoscopy   959           120                           43.8               15.1       47.4       Oral MVI, Fe\*         17.9
  2014   Salgado W Jr      Brazil            Retrospective   Open          102           48                            41.9               14.8       49.7       Oral MVI               4.9
  2014   Ledoux S          France            Prospective     Laparoscopy   144           36                            42.9               9.7        48.2       Oral MVI, B~12~\*      0

Fe\*: Therapeutic iron supplementation; B~12~\*: therapeutic intramuscular vitamin B~12.~

B~12~\#: Augmented with intramuscular vitamin B~12~ prophylaxis.

BMI, body mass index; NR, not reported; Oral MVI, prophylactic oral tablet with multivitamin and mineral supplement.

The proportion of patients with anaemia increased significantly by 8.4% (95% CI 2.8% to 14.0%) 1 year after the surgery ([table 2](#BMJOPEN2014006964TB2){ref-type="table"} and [figure 2](#BMJOPEN2014006964F2){ref-type="fig"}, included nine studies, 3932 patients), from baseline 12.2% (95% CI 8.8% to 15.6%) to 20.9% (95% CI 14.7% to 27.1%). Prevalence of anaemia at 24 and 36 months of follow-up elevated to 25.9% (95% CI 17.9% to 33.8%) and 23.1% (95% CI, 13.6% to 32.7%), respectively. In parallel, a continuous decline in haemoglobin (11 studies, 4548 patients) and haematocrit (three studies, 620 patients) levels after surgery was also observed (see online supplementary table 1A, B).

###### 

Proportion of study participants with anaemia before and after RYGB surgery

                                                   Before surgery        6 months              12 months             24 months             36 months            Δ6 month            Δ12 month             Δ24 month            Δ36 month                                      
  --------------------------- -------------------- --------------------- --------------------- --------------------- --------------------- -------------------- ------------------- --------------------- -------------------- ----------- ------ ------ ------ ------ ------ -------------------------------------------
  2009                        Toh SY               7/113                 6.0                   ­                     --                    10/58                17.0                --                    --                   --          --     --     11.0   --     --     Hb: men \<13.0 g/dL; women \<11.9 g/dL
  2011                        von Drygalski A      125/1037              12.0                  70/559                12.5                  43/371               11.6                35/153                22.9                 --          --     0.5    −0.4   10.9   --     Hb: men \<13.0 g/dL; women \<12.0 g/day L
  2011                        Cable CT             156/1009              15.5                  --                    --                    259/720              36.0                --                    --                   --          --     --     20.5   --     --     Hb: men \<14.0 g/dL; women \<12.0 g/dL
  2012                        Blume CA             11/170                6.5                   37/170                21.8                  32/170               18.8                58/170                34.1                 57/170      33.5   15.3   12.3   27.6   27.0   Hb: men \<13.0 g/day L; women \<12.0 g/dL
  2012                        Aarts EO             27/377                7.2                   50/377                13.3                  71/377               18.8                --                    --                   --          --     6.1    11.6   --     --     Hb: men \<13.5 g/dL; women \<11.9 g/dL
  2012                        Dallal RM            97/590                16.4                  --                    --                    162/590              27.5                --                    --                   --          --     --     11.1   --     --     Hct: men \<39%; women \<35%
  2013                        Moizé V              65/294                22                    61/294                20.8                  59/294               19.9                46/259                17.7                 35/203      17.2   −1.2   −2.1   −4.3   −4.8   Hb: men \<13.7 g/dL; women \<12.2 g/dL
  2014                        Salgado W Jr         22/102                21.6                  --                    --                    25/97                25.8                26/85                 30.6                 27/89       30.3   --     4.2    9.0    8.7    Hb: men \<13 g/dL; women \<12 g/dL
  2014                        Ledoux S             9/144                 6.0                   --                    --                    17/144               12.0                --                    --                   15/115      13.0   --     6.0    --     7.0    Hb: men \<11.5 g/dL; women \<11.5 g/dL
  Summary estimate (95% CI)   12.2 (8.8 to 15.6)   16.6 (12.1 to 21.0)   20.9 (14.7 to 27.1)   25.9 (17.9 to 33.8)   23.1 (13.6 to 32.7)   4.8 (−1.1 to 10.8)   8.4 (2.8 to 14.0)   10.8 (−3.3 to 24.8)   9.4 (−4.7 to 23.5)                                                  
  I^2^                        89.8                 79.6                  93.8                  81.9                  87.6                  81.9                 88.2                91.7                  91.3                                                                

Hb, haemoglobin; Hct, haematocrit; RYGB, Roux-en-Y gastric bypass.

![Forest plot for proportion of study participants with anaemia before RYGB and 12 months after Roux-en-Y gastric bypass (RYGB).](bmjopen2014006964f02){#BMJOPEN2014006964F2}

To elucidate the cause of anaemia after RYGB, iron deficiency was first investigated, with ferritin and iron levels. The proportion of study participants with low ferritin levels rose by 4.1% (95% CI −2.2% to 10.4%) at 12 months after surgery, from 7.9% (95% CI 0.95% to 14.8%) at baseline to 13.4% (95% CI 3.5% to 23.4%) ([figure 3](#BMJOPEN2014006964F3){ref-type="fig"}A and [table 3](#BMJOPEN2014006964TB3){ref-type="table"}, included four studies, 685 patients). The proportion of patients with low ferritin levels rose to 23.0% (95% CI 9.1% to 36.9%) and 26.5% (95% CI 20.6% to 32.4%) at 24 and 36 months, respectively. Pooled estimates for mean serum ferritin levels (see online supplementary table 2A, four studies, 1512 patients) had the baseline at 87.6 ng/mL (95% CI 75.4 to 99.9), which declined to 55.5 ng/mL (95% CI 43.0 to 68.0) at 24 months follow-up. In contrast, the proportion of study participants with low levels of serum iron ([figure 3](#BMJOPEN2014006964F3){ref-type="fig"}B and [table 4](#BMJOPEN2014006964TB4){ref-type="table"}, four studies, 685 patients) and mean serum iron concentration (see online supplementary table 2B, six studies, 2072 patients) did not change significantly.

###### 

Proportion of study participants with low ferritin level before and after RYGB surgery

                                                   Before surgery       6 months             12 months            24 months             36 months           Δ6 month             Δ12 month            Δ24 month            Δ36 month   Cut-off point in ferritin level                               
  --------------------------- -------------------- -------------------- -------------------- -------------------- --------------------- ------------------- -------------------- -------------------- -------------------- ----------- --------------------------------- ------ ------ ------ ------ ----------------------------------
  2006                        Madan AK             4/67                 6.0                  11/56                20.0                  6/37                16.0                 --                   --                   --          --                                14.0   10.0   --     --     NR
  2009                        Toh SY               2/103                2.0                  --                   --                    8/53                15.0                 --                   --                   --          --                                --     13.0   --     --     \<15 ng/mL
  2012                        Blume CA             9/170                5.3                  7/170                4.1                   7/170               4.1                  27/170               15.9                 40/170      23.5                              −1.2   −1.2   10.6   18.2   Men \<22 ng/mL; Women \<10 ng/mL
  2013                        Moizé V              55/294               18.6                 56/294               19.0                  58/294              19.8                 78/259               30.1                 60/203      29.5                              0.4    1.2    11.5   10.9   \<15 ng/mL
  Summary estimate (95% CI)   7.9 (0.95 to 14.8)   13.9 (2.0 to 25.8)   13.4 (3.5 to 23.4)   23.0 (9.1 to 36.9)   26.5 (20.6 to 32.4)   2.4 (−4.2 to 9.0)   4.1 (−2.2 to 10.4)   11.0 (6.2 to 15.8)   14.7 (7.5 to 21.8)                                                                             
  I^2^                        92.4                 94.1                 91.3                 92.1                 42.2                  63.5                62.9                 0.0                  45.7                                                                                           

NR, not reported; RYGB, Roux-en-Y gastric bypass.

###### 

Proportion of study participants with low level of serum iron before and after RYGB surgery

                                                   Before surgery       6 months             12 months           24 months            36 months            Δ6 month               Δ12 month              Δ24 month              Δ36 month   Cut-off point in serum iron level                                  
  --------------------------- -------------------- -------------------- -------------------- ------------------- -------------------- -------------------- ---------------------- ---------------------- ---------------------- ----------- ----------------------------------- ------ ------- ------- ------- ---------------------------------
  2006                        Madan AK             9/64                 14.0                 6/56                10.0                 2/36                 6.0                    --                     --                     --          --                                  −4.0   −8.0    --      --      NR
  2009                        Toh SY               15/100               15.0                 --                  --                   11/53                21.0                   --                     --                     --          --                                  --     6.0     --      --      \<50 μg/dL
  2012                        Blume CA             10/170               5.9                  10/170              5.9                  2/170                1.2                    15/170                 8.8                    14/170      8.2                                 0      −4.7    2.9     2.3     Men \<49 μg/dL; women \<37μg/dL
  2013                        Moizé V              78/294               26.5                 54/294              18.2                 47/294               15.9                   27/259                 10.6                   25/203      12.5                                −8.3   −10.6   −15.9   −14.0   \< 50 μg/dL
  Summary estimate (95% CI)   15.3 (4.7 to 25.9)   11.4 (2.8 to 20.0)   10.5 (0.6 to 20.3)   9.8 (7.0 to 12.6)   10.2 (6.0 to 14.4)   −3.7 (−9.4 to 2.0)   −5.6 (−10.8 to −0.4)   −6.4 (−24.9 to 12.0)   −5.7 (−21.7 to 10.3)                                                                                  
  I^2^                        93.1                 89.0                 94.2                 0.0                 46.9                 47.5                 47.0                   94.8                   92.6                                                                                                  

NR, not reported; RYGB, Roux-en-Y gastric bypass.

![Forest plot for proportion of study participants with (A) ferritin (B) serum iron (C) vitamin B~12~ and (D) folate deficiencies, before Roux-en-Y gastric bypass (RYGB) and 12 months after RYGB.](bmjopen2014006964f03){#BMJOPEN2014006964F3}

The proportion of patients with low vitamin B~12~ levels increased 3.6% (95% CI −1.2% to 8.4%) from 2.3% (95% CI 1.1% to 3.6%) at baseline, to 6.5% (95% CI 1.8% to 11.1%) at 12 months of follow-up ([figure 3](#BMJOPEN2014006964F3){ref-type="fig"}C and [table 5](#BMJOPEN2014006964TB5){ref-type="table"}, included five studies, 829 patients), with a consistent decrease in mean vitamin B~12~ levels (see online supplementary table 2C, included seven studies, 2204 patients). A continuous increase in the proportion of patients with vitamin B~12~ deficiency was noted, that is, 5.4% (95% CI 3.3% to 7.6%) at 24 months and 7.2% (95% CI 4.6% to 9.7%) at 36 months. In contrast, no obvious change was found for the proportion of patients with low folate levels ([figure 3](#BMJOPEN2014006964F3){ref-type="fig"}D and [table 6](#BMJOPEN2014006964TB6){ref-type="table"}, four studies, 535 patients), nor for mean folate levels, before and after surgery (see online supplementary table 2D, five studies, 1840 patients). Overall, the proportion of patients with anaemia and with deficiencies in iron, ferritin, folate and vitamin B~12~ at different time points varied across individual studies, with I^2^ values raised as high as 94.8%, indicating substantial heterogeneity between studies. In contrast, I^2^ values for ferritin, serum iron, folate and vitamin B~12~ levels were almost equal to zero, which may be due to large variance for these outcomes within studies. For the proportion of patients with anaemia 12 months after surgery, publication bias was not detected by the funnel plot (p=0.754 with Begg\'s test, or p=0.978 with Egger\'s test) ([figure 4](#BMJOPEN2014006964F4){ref-type="fig"}). The number of studies for other primary outcomes was scarce (≤5 studies), which may be statistically underpowered; these studies were thus not evaluated in this analysis.

###### 

Proportion of study participants with vitamin B~12~ deficiency before and after RYGB surgery

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Before surgery   6 months        12 months      24 months      36 months       Δ6 month        Δ12 month      Δ24 month      Δ36 month   Definition of deficiency                             
  --------------------------- -------------- ---------------- --------------- -------------- -------------- --------------- --------------- -------------- -------------- ----------- -------------------------- ------ ------ ----- ----- -------------
  2006                        Madan AK       3/59             5.0             0/56           0\*            0/36            0\*             --             --             --          --                         −5.0   −5.0   --    --    NR

  2009                        Toh SY         1/88             1.0             --             --             6/56            11.0            --             --             --          --                         --     10.0   --    --    \<196 pg/mL

  2012                        Blume CA       5/170            2.9             6/170          3.5            6/170           3.5             9/170          5.3            12/170      7.1                        0.6    0.6    2.4   4.2   \<211 pg/mL

  2013                        Moizé V        5/294            1.8             9/294          2.9            18/294          6.2             14/259         5.5            12/203      5.8                        1.1    4.4    3.7   4.0   \<250 pg/mL

  2014                        Ledoux S       7/144            5.0             --             --             23/144          16.0            --             --             13/115      11.0                       --     11.0   --    6.0   \<190 pg/mL

  Summary estimate (95% CI)   2.3\           1.9\             6.5\            5.4\           7.2\           −0.3\           3.6\            3.2\           4.4\                                                                            
                              (1.1 to 3.6)   (0 to 4.4)†      (1.8 to 11.1)   (3.3 to 7.6)   (4.6 to 9.7)   (−3.3 to 2.7)   (−1.2 to 8.4)   (0.7 to 5.8)   (1.8 to 7.0)                                                                    

  I^2^                        22.9           85.8             92.8            0.0            17.1           48.8            77.7            0.0            0.0                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data were included in the analysis with a continuity correction factor of 0.01.

†The lower limits of 95% CI were truncated as zero due to negative values.

NR, not reported; RYGB, Roux-en-Y gastric bypass.

###### 

Proportion of study participants with folate deficiency before and after RYGB surgery

                                                  Before surgery     6 months          12 months          24 months         36 months            Δ6 month             Δ12 month              Δ24 month            Δ36 month   Definition of deficiency                               
  --------------------------- ------------------- ------------------ ----------------- ------------------ ----------------- -------------------- -------------------- ---------------------- -------------------- ----------- -------------------------- ------ ------ ------ ------ -------------
  2006                        Madan AK            1/62               2.0               2/54               3.0               3/37                 8.0                  --                     --                   --          --                         1.0    6.0    --     --     NR
  2009                        Toh SY              0/65               0\*               --                 --                0/22                 0\*                  --                     --                   --          --                         --     0      --     --     \<3.1 ng/mL
  2012                        Blume CA            11/170             6.5               8/170              4.7               2/170                1.2                  3/170                  1.8                  1/170       0.6                        −1.8   −5.3   −4.7   −5.9   \<2.8 ng/mL
  2014                        Ledoux S            3/144              2.0               --                 --                6/144                4.0                  --                     --                   1/115       1.0                        --     2.0    --     −1.0   \<3.0 ng/mL
  Summary estimate (95% CI)   2.2 (−0.3 to 4.7)   4.1 (1.5 to 6.7)   1.6 (0 to 3.5)†   1.8‡ (0 to 3.8)†   0.7 (0 to 1.7)†   −0.6 (−4.3 to 3.1)   −0.3 (−3.5 to 2.9)   −4.7‡ (−8.9 to −0.5)   −3.3 (−8.1 to 1.5)                                                                      
  I^2^                        80.7                0.0                67.0              --                 0.0               0.0                  67.0                 --                     74.4                                                                                    

\*Data were included in the analysis with a continuity correction factor of 0.01.

†The lower limits of 95% CI were truncated as zero due to negative values.

‡Only one study for the analysis.

NR, not reported; RYGB, Roux-en-Y gastric bypass.
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Discussion {#s4}
==========

Several studies reported that a substantial proportion of patients already had anaemia prior to RYBG surgery, as well as having deficiencies in iron, folate and vitamin B~12~. This can probably be explained by the fact that obesity is a known risk factor for nutrient deficiencies despite an excessive calorie reserve.[@R42] Our meta-analysis observed a nearly twofold increase in anaemia occurrence at 12 months after RYGB surgery, with an exacerbating declining of haemoglobin/haematocrit over time. However, the iron level may not decrease after RYGB and folate deficiency is correctable with oral multivitamin supplementation. It is important to intervene early on in cases of iron deficiency anaemia with ferritin profiling, and augmented supplementation is important for vitamin B~12~, the deficiency of which may occur later, from 12 months postoperation on.

In our current meta-analyses, frequency of ferritin deficiency increased by twofold in patients at 6 months after surgery, and this trend became substantially aggravated at 24 and 36 months. However, no significant change in serum iron concentration after RYGB surgery was found. Since serum ferritin is a more specific and early indicator for iron deficiency anaemia, the low ferritin levels with stable serum iron concentrations suggest reduced body iron capacity.[@R45] Although ferritin is also an acute-phase protein, and elevation of ferritin has been reported as early as the first month after surgery,[@R15] the decreasing trend in ferritin level is observed at 6 months or longer after surgery, when no active inflammation is expected.

Reasons for iron deficiency can be attributed to the bariatric procedure of RYGB, which have dual effects on intake restriction and malabsorption.[@R46] After RYGB surgery, patients dramatically reduce their caloric intake with concomitant changes in eating behaviour and dietary adherence.[@R47] Postoperative changes in food preferences, including intolerance for meats and dairy products, have been reported in patients following RYGB.[@R27] [@R48] Hypochlorhydria, the virtual absence of hydrochloric acid secretion by the stomach, is also known to decrease the bioavailability of dietary iron.[@R49] Furthermore, after RYGB, ingested food bypasses through most of the stomach and duodenum, as well as a significant portion of the jejunum, where physiological iron absorption takes place.[@R15] [@R50]

Previous evidence has shown that vitamin B~12~ is malabsorbed following RYGB surgery, since duodenum as the physiological absorption segment was bypassed and that is even exaggerated by inadequate secretion of intrinsic factor and limited gastric acid.[@R49] [@R51] [@R52] The body\'s reserves of vitamin B~12~ normally outweigh daily requirement and, therefore, earlier deficits in vitamin B~12~ may not occur in the short-term observation after RYGB surgery.[@R28] Furthermore, postoperative intramuscular or regular intranasal administration of vitamin B~12~ was reported to reduce the incidence of deficiency.[@R53] [@R54] The absence of folate deficiency suggests that folate may not be a major cause of anaemia after RYGB. Folate absorption occurs throughout the entire small intestine, and the deficiency is primarily induced by shortage of dietary intake, which is correctable by regular supplementation.[@R52] [@R55] Therefore, the anaemia occurring after 12 months postoperation may be related to vitamin B~12~ deficiency rather than folate deficiency. Furthermore, the early impact observed with declining ferritin level after 6 months postoperation and even exaggerating later at 24 and 36 months of follow-up, suggests the need for augmented nutrition management.

Our study highlights the importance of detecting and monitoring the occurrence of anaemia and related nutrient deficiencies among patients receiving RYGB surgery. The preoperative screening of biochemical and haematological profiles of patients undergoing RYGB surgery is essential for early detection and better correction of nutritional deficiencies.[@R56] Prophylactic oral supplements may be indicated to prevent possible side effects, especially for high-risk populations.[@R57] [@R58] Nutritional deficiencies after RYGB surgery can still occur despite pharmacotherapy prevention.[@R16] [@R59] To prevent anaemia and the related complications of nutrient deficiencies, patients who do not respond to oral supplementation should be referred early on for parenteral replacement therapy.[@R38] Mean corpuscular volume, and reticulocyte and a simple blood smear, may be useful in differential diagnosis of anaemia, and bone marrow biopsy is warranted to investigate the aetiology of persistent anaemia associated with cytopaenia.[@R22] [@R60] Long-term consistent monitoring of nutritional complications secondary to RYGB surgery is recommended.[@R23] [@R58]

This is a systematic review of studies published in English (ie, single language) to look at the effect of RYGB surgery on anaemia. The study benefits from the inclusion of a large number of patients, and the results showed there is not much uncertainty about the effect of the surgery on anaemia. However, there is no formal quality assessment, and the publication bias was only evaluated for the proportion of study participants with anaemia 12 months after RYGB. Most of the included studies were retrospective in nature and some of them had high loss-to-follow-up rates or incomplete ascertainment of nutrient deficiencies among participants. Second, there were substantial differences in preoperative prophylactic and postoperative nutritional management across studies, and the heterogeneity of RYGB procedures carried out by laparotomy or laparoscopy with differences in the length of the Roux-en-Y loop. Third, monitoring of patients and the quality in reporting outcomes of interest varied across studies. We did not define specific cut-off values for our outcomes of interest because different criteria were used in different studies. Although such discrepancies reflect clinical practice, this may increase variation of summary estimates. However, we got consistent findings either based on dichotomous outcomes or continuous variables (such as % of study participants with anaemia and Hb/Hct levels), which supported the robust estimate in our research. Fourth, other factors related to anaemia, such as vitamins B~1~, A, D, E and K, and trace elements of copper and zinc,[@R61] as well as changes in inflammation levels,[@R60] [@R64] were not assessed due to lack of data in the included studies. Fifth, this study was susceptible to inherent drawbacks that reflect the challenges of using tertiary data for meta-analysis. For example, although we observed profound changes in the proportion of patients with anaemia, ferritin and vitamin B~12~ deficiencies after surgery, the missing rate for each outcome at 12, 24 and 36 months obviously varied. This may result in different studies being enrolled at individual time points, increase the complexity of evaluating changes in outcome measurements over time, and induce substantial heterogeneities in summary estimates. Also, as mentioned above, none of the included studies provided the variance for changes of each outcome from baseline. This precluded the accurate calculation of covariance of outcomes between different time points and led to overestimation of the variability for changes of anaemia status and related nutrient deficiencies from baseline. Finally, limited data from published reports may still be insufficient to precisely estimate the cumulative incidence of anaemia and related nutrient deficiencies, due to limited sample size and follow-up time. As more data become available through well designed and properly conducted large observational studies with long duration, more hypotheses about haematological and nutritional complications following RYGB surgery can be explored in the future.

Conclusions {#s5}
===========

Morbid obesity, although modifiable under bariatric surgery, is a life-long disease. Even with supplementation, anaemia and deficiencies of iron and vitamin B~12~ may develop as early as 6 months postoperatively and exacerbate over time. Anaemia may occur with declining body reserve of vitamin B~12~ and deteriorating iron metabolism, which can be identified early by ferritin levels, but can also be masked by those of serum iron and declining body reserve of vitamin B~12~. The possible risk of haematological and nutritional sequelae should be taken into consideration in clinical practice. Regular surveillance of all RYGB candidate and persistent follow-up with comprehensive nutrient profiles is strongly recommended to improve the overall health status of individuals with morbid obesity.
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